INVESTMENT

DECK
 disclaimer
This presentation has been prepared by 969 (the “Company”) for investors, solely for informational purposes.
disclaimer About scientific stuff
The information contained herein has been prepared to assist prospective investors in making their own
evaluation of the Company and does not purport to be all-inclusive or to contain all of the information a
prospective or existing investor may desire. You should consult your own legal, regulatory, tax, business,
investment, financial and accounting advisers to the extent that you deem necessary, and you must make
your own investment decision regarding the securities of the Company based upon your own judgment
and advice from such advisers, as you deem necessary, and not upon any views expressed herein. The
Company makes no representation or warranty as to the accuracy or completeness of this information
and shall not have any liability for any representations (expressed or implied) regarding information
contained in, or for any omissions from, this information or any other written or oral communications
transmitted to the recipient in the course of its evaluation of the Company.

Certain statements in this presentation constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements
regarding intent, belief, or current expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue reliance should not be placed on any
such forward-looking statements, which are based on information available to us on the date of this
presentation. These forward-looking statements are based on current estimates and assumptions and are
subject to various risks and uncertainties. Thus, actual results could be materially different. The Company
expressly disclaims any obligation to update or alter statements whether as a result of new information,
future events, or otherwise, except as required by law.
Prospective investors will be expected to have conducted their own due diligence investigation regarding
these and all other matters pertinent to investment in the Company.

The securities of the Company have not been and will not be registered under the U.S. Securities Act of
1933, as amended, or any U.S. state securities laws. Neither this presentation nor anything contained
herein shall form the basis of any contract or commitment whatsoever.
OVERVIEW & THESIS
TheThenamename of this
of this fund fund is Inspired
is Inspired by by Methuselah
Methuselah who
who
lived to lived
be 969 to years
be 969 in years in the Bible.
the Bible.
969969 is dedicated
is dedicated to advancing
to advancing human
human longevity
longevity and
and well-being.
well-being. We aimWe aim to
to seize theseize the substantial
substantial market
market opportunity
opportunity in the longevity in thesector,
longevity sector, on
capitalizing
thecapitalizing
convergence onof thecutting-edge
convergencetechnology,
of cutting-edge
technology,shifts,
demographic demographic
and heightened shifts, and heightened
consumer
consumer
interest interest
in healthy aging.in healthy aging. With
With support fromsupport
visionary
from visionary
investors and innovativeinvestors and innovative
startups; startups;
and by harnessing
theand by harnessing
expertise of industry theleader
expertiseDave ofAsprey
industryand leader
Dave Asprey
collaborating withand collaborating
Percival and Brock with Percival
Pierce's and
family
Brock
office; 969Pierce's family office;
is positioned to make 969 is positioned to
impactful
make impactful
investments that not investments
only deliverthat not onlyfinancial
attractive deliver
attractive
returns but alsofinancial
contributereturns tobut
the also contributeofto
advancement
the advancement
human longevity. of human longevity.
OurOur goalgoal
is tois collaborate
to collaborate withwith experts
experts andand
innovators,
innovators, leveraging
leveraging theirtheir expertise
expertise from fromtoptop
research
research institutions
institutions andand biotechnology
biotechnology companies,
companies,
to develop to develop
ethical, effective, ethical, effective, solutions
and accessible and
foraccessible
extended solutions for extended
healthy lifespans. healthy
The time is now to
lifespans.
invest The time
in longevity, andiswe now aretoexcited
invest in tolongevity,
be at the
and weofare
forefront thisexcited
endeavor. to be at the forefront of this
endeavor.

969
Human longevity has evolved remarkably. Early humans faced short life expectancies due to hazards and predation. Agriculture marked
progress, enabling stable food sources and population growth. Some ancient individuals lived into their 60s and 70s. The Middle Ages
brought challenges like famine and disease, reducing life expectancies. Science and medicine advances during the Renaissance and
Enlightenment improved longevity. The Industrial Revolution enhanced living conditions, nutrition, and healthcare access. The 20th century
saw significant life expectancy gains due to medical progress and healthier lifestyles. Today, global life expectancy rises, with disparities tied
to socioeconomic factors and healthcare access. Ongoing research offers hope for extending lifespan.
 Problem
Society is confronted with a
burgeoning challenge in the
realm of aging and longevity.
The world's aging population
presents an unprecedented
need for innovative solutions
to address age-related
diseases, healthcare costs,
and the overall quality of life
in our later years.
Aging-Related
Health Issues
Chronic Diseases: 80% of
older adults have at least one
chronic condition.
Rising Healthcare Costs: The
global cost of healthcare for
older adults is projected to
reach $15 trillion by 2050.
Decreased Quality of Life:
Approximately 1 in 3 older
adults experience a decline in
their quality of life due to
age-related issues.
Global Aging Statistics
Aging population on the
rise: By 2050, the number of
people aged 60+ will double
from the current 1 billion to 2
billion.
Age-related diseases
becoming more prevalent:
Alzheimer's disease cases
are expected to triple by
2050.
Healthcare systems
strained: Aging populations
will require an additional 24
million healthcare workers
globally by 2030.
 Investing in Tomorrow

Play a significant part in paving the

way towards a future of increased
human health and longevity.
Enhance the quality of life for aging
individuals.

The Promise of Longevity Science

Belief in science and tech to reshape

aging.
Support transformative innovations.
The global anti-aging market is projected to reach
$66.2 billion by 2025, with a CAGR of 5.7% (Market
Data Forecast).

The global longevity and anti-senescence therapy

market was valued at $329.8 million in 2019 and is
anticipated to grow at a CAGR of 8.6% from 2020 to
2027 (Gitnux Market Data).

Venture capital funds dedicated to aging research

and longevity startups raised over $850 million.
(Business Insider)

The broader longevity market spans multiple

sectors, including biotechnology, pharmaceuticals,
digital health, and wellness, with growth potential
in each segment.

Increased Interest
The field of longevity-focused funds
has gained significant attention in
recent years as the aging population
grows, leading to increased demand
for innovative therapies.
Increased Interest
The field of longevity-focused
funds has gained significant
attention in recent years as the
aging population grows, leading
to increased demand for
Collaborations Diversification
innovative therapies. globally by
2030.
Longevity-focused funds often Longevity funds are diversifying their
collaborate with academic institutions, portfolios to include a range of
pharmaceutical companies, and research interventions, from pharmaceuticals to
organizations to advance research and regenerative therapies and digital health
development efforts. solutions.
 Genomic instability: Genetic damage
Biogerontology: Biology of Aging accumulation.

Telomere attrition: Shortening

chromosome caps.

Epigenetic alterations: Gene expression

changes.

Loss of proteostasis: Misfolded proteins.

Deregulated nutrient-sensing:
Metabolism pathways.

Mitochondrial dysfunction: Energy

powerhouse failure.

Cellular senescence: Accumulation of

older cells.

Stem cell exhaustion: Decline in

Companies focused on aging or age-related diseases are tackling one or regenerative cells.
more of these biological traits to find promising therapeutic candidates. In
the next sections, we’ll explore how each of these are being targeted: Altered intercellular communication:
Disrupted cell communication.
 General Partner: brock pierce
Multi-dimensional approach to the fund.
Expertise in technology, blockchain, and unconventional funding.
Enhancing the fund's potential reach and impact.

Brock Pierce is a futurist, entrepreneur, philanthropist and venture capitalist with an

extensive 20+ year track record of founding, advising and investing in disruptive
businesses and innovative technologies. He's credited with pioneering the market
for digital currency and has raised more than $5B for companies he has founded.
Pierce is the Chairman of the Bitcoin Foundation and co-founder of Block.one (the
company that launched EOS.IO, which raised more than $4b, (largest ICO ever),
Blockchain Capital, Tether (the first stablecoin that digitized and backed the US
dollar on the blockchain. Tether currently has the most transactional volume of any
cryptocurrency), and Mastercoin (first ICO). Pierce is an early investor in Bitcoin and
one of the largest investors in the Ethereum crowdsale. Pierce ran for President of
the United States as an Independent, receiving the first-ever US presidential vote
cast on the blockchain. Pierce currently is Chairman of Percival, his business office,
that invests across asset classes with a focus on early-stage investments in deep
tech. Pierce has been a long supporter of MAPS (Multidisciplinary Association for
Psychedelic Studies), a pre-IPO investor in ATAI Life Sciences, a Germany-based
clinical-stage biopharmaceutical company and is also an investor in Filament Health,
a Canadian-based clinical-stage natural psychedelic development company.
General Partner: Dave Asprey
Dave Asprey's knowledge and resources within the longevity space and his role as an angel investor in various successful ventures
showcases his ability to identify high-potential opportunities and contribute to their growth. His involvement adds credibility and
strategic value to the longevity fund.

The Longevity Industry faces several challenges, such as regulatory hurdles, ethical considerations, the need for long-term clinical trials,
and skepticism from both public and scientific communities about the feasibility of significantly extending human lifespan. Dave Asprey is
an ideal partner to navigate these challenges.
investment team

Chris Valentine Takashi Yanagi Diego Viladoms

Founder of Celeres Capital Investment Associate Entrepreneur in Residence
market opportunity
The global anti-aging market is projected to reach $66.2 billion by
2025, with a CAGR of 5.7% (M
arket Data Forecast).
The global longevity and anti-senescence therapy market was
valued at $329.8 million in 2019 and is anticipated to grow at a
CAGR of 8.6% from 2020 to 2027 (Gitnux Market Data).
Venture capital funds dedicated to aging research and longevity
startups have raised over $850 million.
The broader longevity market spans multiple sectors, including
biotechnology, pharmaceuticals, digital health, and wellness, with
growth potential in each segment.

market TRENDS
Increasing consumer awareness of the possibilities of extending
human lifespan is driving demand for products and services that
contribute to healthy aging.
Technological breakthroughs in areas such as CRISPR-based gene
editing, stem cell therapies, and biomarker identification are
accelerating the development of longevity-enhancing solutions.
target market
We offer investors exposure to cutting-edge advancements in longevity and human health technologies, driving
the future of healthcare and well-being.

Genetic Therapies: USD 18.61 billion in 2022 and is projected to reach a value of USD 93.78 billion by 2030,
poised to grow at a projected CAGR of 22.41% from 2022 to 2030. (BioSpace, 2022)
Biotechnology: USD 852.88 billion in 2020 and is projected to reach a value of USD 3.44 trillion by 2030,
poised to grow at a projected CAGR of 17.83% from 2021 to 2030. (BioSpace, 2022)
Regenerative Medicine: USD 22.24 billion in 2022 and is projected to reach a value of USD 174.72 billion by
2032 with a CAGR of 22.8% from 2023 to 2032. (Precedent Research, 2023)
Digital Health Innovations: USD 169.36 Billion in 2022 and is projected to reach a value of USD 586.59 Billion
by 2030 at a CAGR of 16.80% over the forecast period. (LinkedIn, 2023)
Rare diseases treatment: USD 119.71 billion in 2021 and is projected to reach a value of USD 335.99 billion by
2030, growing at a CAGR of 12.15% from 2022 to 2030 (BioSpace, 2022)
Health and Wellness: US$ 4 trillion in 2020 and is projected to reach a value of US$ 6.75 trillion by 2030,
expanding at a CAGR of 5.2% from 2021 to 2030. (BioSpace, 2022)

Other notable fields:

Technology and AI: (predict and prevent age-related health issues), Senolytics (interventions that target
senescent cells), Psychedelics (breakthrough therapies aimed at improving mental health and well-being).
Warehouse
HelioFlux (prospect) Igniton (prospect)
Cancer detection and Doubling brain voltage
prevention company and increasing telomeres
with a technology process
out of CERN. Raising
$30M on a $4M pre

RMS (prospect) Minicircle (prospect)

RMS is attempting to Doing gene therapy for
cure diabetes using non- longevity. I just had the
embryonic stem cells to treatment. Average of
turn into insulin nine years of epigenetic
producing cells founded age lost from a single
in 2012. Excellent team injection. Some super
and advisors. Their responders are losing 20
competitors are acquired to 30 years off of their
early signaling market measured age.
demand.
OPERATIONS
We seek visionary founders and innovative startups dedicated to tackling global
longevity challenges.
Our team employs a rigorous selection process, evaluating critical data points, leveraging
our deep technical expertise:

Selection sequence:
Alignment with Longevity Vision Comprehensive Due Diligence

Does the venture solve an international large i. In-house Longevity Expertise

enough problem with a scalable approach that ii. Thorough Team Assessment, Industry References
can generate attractive multiples in revenue if iii. Extensive Market Research & Early Adopter Validation
successful? iv. Legals & Compliance Checks

i. Inbound Investment Dealflow,

Referrals, Outbound Investment Dealflow Investment decision
ii. Initial Pitch Evaluation
iii. Presentation to Core Team
Strategic Deal Management & Value Enhancement
allocation
Avg. Company Investment: USD 2 million

Potential investment count: 15 early stage companies

Avg. Valuation: USD 10 million pre-money

Follow-on after Seed: Fund investors can use our pro-rata to follow on

Coinvestment: Fund investors will be able to co-invest via SPVs

economics
Lead GPs (1-10% of Fund): Brock Pierce, 50% Dave Asprey, 50%

Additional GP Candidate(s): Jim Armstrong

GP Commitments: $1M

Investment Manager: Celeres Capital, 20% Fee/Carry points, comprised portion for Celeres and portion to
investment team

Duration: 7 years with two 1 year extensions (optional), 9 years in total

Check Size: Minimum $1M for institutions, Minimum $250K for individuals

Management Fee: 2.5% if raising under $50M, 2.0% if raising over $50M

Carry: 25% if raising under $50M, 20% if raising over $50M

Target Total Fundraise: $96,900,000

Target First Close Date: 12/31/23

Expected # of LPs: 25
Skepticism & Risks:
Moral, ethical, and Some scientists Studying age-related
religious concerns question the feasibility therapies poses
may arise about of significantly challenges due to
extending longevity extending human long-term evaluation
through "magic pills" needs.
lifespan, raising health
or injections. risks.
.
Study Highlight:
A study (Dec 2017) titled “Intercellular competition and the inevitability of
multicellular aging,” illustrated that even if we were able to target one
hallmark of aging, we may also simultaneously be stimulating other processes
that speed up our aging and could even cause diseases in the process.

Controversies:
Overpopulation
Concerns about increased population with longer lifespans.
Debate on whether technological innovations can offset resource limitations
Social Inequities:
Potential for wealth-based disparities in access to anti-aging treatments.
Possible wide variations in lifespans across different socio-economic classes.
CONSIDERATION:
Cost-effectiveness of anti-aging therapeutics compared to traditional
medical procedures and drugs.
 october, 2023

INVESTMENT
DECK
Contact Us

969